Work

Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis

Year: 2006

Type: article

Study design: Clinical Trial

Source: Journal of Infection

DOI: 10.1016/j.jinf.2006.03.003

Authors: David W. Denning, Kieren A. Marr, Wendi M. Lau, David P. Facklam, Voravit Ratanatharathorn, Cornelia Becker, Andrew J. Ullmann, Nita L. Seibel, Patricia M. Flynn, Jo-Anne H. van Burik, Donald N. Buell, Thomas F. Patterson

Institutions: University of Manchester, Wythenshawe Hospital, University of Washington, Fred Hutch Cancer Center, Astellas Pharma (United States), Wayne State University, The Barbara Ann Karmanos Cancer Institute, Johannes Gutenberg University Mainz, University Medical Center of the Johannes Gutenberg University Mainz, Children's National, St. Jude Children's Research Hospital, University of Minnesota, The University of Texas at San Antonio Health Science Center

Language: English

Topic: Antifungal resistance and susceptibility

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Bristol-Myers Squibb, Pfizer, Astellas Pharma US, Gilead Sciences, Wellcome Trust, European Commission, Eisai, Astellas Pharma, National Institute of Allergy and Infectious Diseases

OpenAlex ID: W1968047266

FWCI: 19.42

Cites: 50

Cited by: 292

Related to: 10